

05th Knowledge Series for Genitourinary Cancers - Best of 2023		
Day 1   11th May, 2024		
Venue- The Pride Aero City Delhi		
Time	Topic	Speaker
08:00- 08:50 AM	<b>Registration &amp; Networking</b>	
08:50- 09:00 AM	<b>Introduction/Welcome message</b>	<b>Dr. Puneet Ahluwalia, Delhi (UO)</b>
	<b>Session Coordinator</b>	<b>Dr. Gopal Sharma, Delhi (UO)</b>
	<b>SESSION 1- Prostate : Non Metastatic</b>	
	<b>Chairpersons</b>	<b>Dr. Sudhir Rawal, Delhi (UO) Dr. Jagdeesh kulkarni(UO)Mumbai, Dr. Neeraj Rastogi, Lucknow (RO)</b>
09:00- 09:07 AM	Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial ( <a href="https://pubmed.ncbi.nlm.nih.gov/38212178/">https://pubmed.ncbi.nlm.nih.gov/38212178/</a> )	<b>Dr Ashish Khanna, Delhi (UO)</b>
09:07- 09:14 AM	Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.( <a href="https://pubmed.ncbi.nlm.nih.gov/37863727/">https://pubmed.ncbi.nlm.nih.gov/37863727/</a> )	<b>Dr Srivatsan Ramani, Chennai (UO)</b>
09:14- 09:21 AM	Accuracy of combined multi-parametric MRI and PSMA PET-CT in diagnosing localized prostate cancer: newer horizons for a biopsy-free pathway	<b>Dr.Rajender Kumar,Chandigarh(UO)</b>
09:21- 09:33 AM	1)OC-0924 Prostate RT In high risk or N+ Moderate vs Extreme hypofractionation (PRIME): An Interim analysis 2)Long-term treatment outcomes from the International Multi-Institutional Stereotactic Body Radiation Therapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium.	<b>Dr Shyam Bisht, Gurugram (RO)</b>
09:33- 09:45 AM	1)PACE-A: An International Phase 3 Randomised Controlled Trial (RCT) Comparing Stereotactic Body Radiotherapy (SBRT) to Surgery for Localised Prostate Cancer (LPCa)—Primary Endpoint Analysis 2)5-Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer	<b>Dr Trinanjan Basu, Mumbai (RO)</b>
09:45- 09:52 AM	FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP)	<b>Dr. Vipul Nautiyal, Dehradun (RO)</b>
09:52- 09:59 AM	Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial	<b>Dr Ashwin Mallya, Delhi (UO)</b>
09:59- 10:04 AM	<b>Expert Comments</b>	By Chairperson
10:04 -10:34 AM	<b>Panel Discussion on above abstracts</b>	
	<b>Moderator</b>	<b>Dr. Ankur Mittal, Rishikesh,(UO)</b>
	<b>Panelist</b>	<b>Dr.Manav suryavanshi,Faridabad(Uo)</b>
	<b>Panelist</b>	<b>Dr Punit Bansal, Ludhiana (UO)</b>
	<b>Panelist</b>	<b>Dr Hemang Bakshi, Ahmedabad (UO)</b>
	<b>Panelist</b>	<b>Dr Pramod Kumar Gupta, Lucknow (RO)</b>
	<b>Panelist</b>	<b>Dr Sweety Gupta, Rishikesh (RO)</b>
	<b>Panelist</b>	<b>Dr Ram Alva, Bangalore (RO)</b>
10:34- 10:44 AM	<b>Take Home Message</b>	<b>Dr Rahul Jena, Bhubaneswar (UO) Dr Vineeta Goel,Delhi (RO)</b>
	<b>Session Coordinator</b>	<b>Dr Mayank Agarwal,Delhi (UO)</b>
	<b>SESSION 2- Prostate : Non Metastatic</b>	
	<b>Chairpersons</b>	<b>Dr. Amlesh Seth,Delhi (UO) Dr Hemang Bakshi, Ahmedabad (UO) Dr. Shikha Goyal,Chandigarh (RO)</b>
10:44- 10:51 AM	<a href="https://pubmed.ncbi.nlm.nih.gov/36912538/">https://pubmed.ncbi.nlm.nih.gov/36912538/</a> Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (PROTECT Trial)	<b>Dr Vishnu Prasad,kochi, (UO)</b>
10:51 - 10:58 AM	MO-0217 Pattern of relapse following hypofractionated radiotherapy of IR prostate cancer in the PROFIT trial 1)Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial 2)Brachtherapy boost improves survival and decreases risk of developing distant metastases compared to EBRT alone in intermediate and high risk group prostate cancer patients	<b>Dr. Bharti Devnani, Jodhpur (RO)</b>
10:58- 11:10 AM	PD-0576 Stereotactic reirradiation for locally recurrent prostate cancer after definitive radiotherapy OC-0628 Salvage low-dose-rate brachytherapy for locally recurrent prostate cancer after radiotherapy	<b>Dr. Jyotirup Goswami Kolkata (RO)</b>
11:10- 11:17 AM	5. <a href="https://pubmed.ncbi.nlm.nih.gov/38261043/">https://pubmed.ncbi.nlm.nih.gov/38261043/</a> Functional Outcomes After Localized Prostate Cancer Treatment (JAMA)	<b>Dr Shashank Agrawal, Kochi (UO)</b>
11:17-11:24 PM	<a href="https://pubmed.ncbi.nlm.nih.gov/37142635/">https://pubmed.ncbi.nlm.nih.gov/37142635/</a> 15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer	<b>Dr Mahendra Pal, Mumbai (UO)</b>
11:24- 11:31 PM	<a href="https://pubmed.ncbi.nlm.nih.gov/38185614/">https://pubmed.ncbi.nlm.nih.gov/38185614/</a> The Oncological and Functional Prognostic Value of Unconventional Histology of Prostate Cancer in Localized Disease Treated with Robotic Radical Prostatectomy: An International Multicenter 5-Year Cohort Study	<b>Dr Harshit Garg, Max Vaishali (UO)</b>
11:31-11:34 PM	<b>Expert Comments</b>	By Chairperson

11:34- 12:04 PM	<b>Panel Discussion on above abstracts</b>	
	<b>Moderator</b>	Dr. Siddharth Yadav, Delhi(UO)
	<b>Panelist</b>	Dr.Jagdeesh kulkarni(UO)Mumbai
	<b>Panelist</b>	Dr Pankaj wadhwa, Gurugram(UO)
	<b>Panelist</b>	Dr Rajiv Yadav,Gurugram (UO)
	<b>Panelist</b>	Dr Dharmender Agarwal, Chandigarh(UO)
	<b>Panelist</b>	Dr Rajpal Singh, Jammu(RO)
	<b>Panelist</b>	Dr.Kausik Bhattacharya,Hyderabad (RO)
	<b>Panelist</b>	Dr. Vivek Anand,Mumbai (RO)
12:04 - 12:14 PM	<b>Take Home message</b>	Dr. Ravi chandran k, Bengaluru Dr Kirthi Koushik, Bengaluru,( RO )
	<b>Session Coordinators</b>	Dr. Nandini Menon,Mumbai (MO)
	<b>SESSION 3 - Prostate : (Metastatic)</b>	
	<b>Chairpersons</b>	Dr. Kumar Prabhash,Mumbai (MO) Dr. Vivek Anand,Mumbai (RO)
12:14- 12:26 PM	CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).[oral session ASCO GU 2024] - Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study [ESMO 2023 1771MO]	Dr. Amit Kumar, (MO) Patna
12:26- 12:33 PM	Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study [European Urology]	Dr. Peush Bajpai, Delhi (MO)
12:33- 12:45 PM	Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial. (JAMA Oncology) Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial [ESMO 2023 LBA86]	Dr. Sunil Chopade,(MO)Mumbai
12:45- 12:57 PM	BRCAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).[oral session ASCO GU 2024] Talazoparib plus Enzalutamide in Metastatic Castration Resistant Prostate Cancer: Subgroup Analyses of the All-Comers Cohort from TALAPRO-2 by HRR Status [ESMO 2023]	Dr Pooja Gupta, Gurgaon (MO)
12:57- 01:09 PM	PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer: [ESMO 2023] Enzalutamide and 177Lu-PSMA-617 in Poor-Risk Metastatic Castration-Resistant Prostate Cancer (mCRPC), a Randomized, Phase 2 Trial. [ESMO 2023]	Dr Dharmender Malik, Delhi, (NM)
01:09- 01:21 PM	Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO) Abstarct -2 Progression-Directed Therapy in Oligoprogressive Castration-Refractory Prostate Cancer: Results of the Prospective Single-Arm Phase II MEDCARE Trial	Dr. Mohd Shuaib (RO- Lucknow)
01:21- 01:26 PM	<b>Expert Comments</b>	By Chairperson
01:26- 01:56 PM	<b>Panel Discussion on above abstracts</b>	
	<b>Moderator</b>	Dr. Akhil Kapoor, Varanasi (MO)
	<b>Panelist</b>	Dr. Rahul Kulkarni, Pune(MO)
	<b>Panelist</b>	Dr. Amit Agrawal, (MO)Raipur
	<b>Panelist</b>	Dr Abhishek Anand, Patna (MO)
	<b>Panelist</b>	Dr. Jagadesan Pandjatcharam, Pondicherry (RO)
	<b>Panelist</b>	Dr Varun Shukla, Varanasi(Nuclear Med)
	<b>Panelist</b>	Dr Sapna Marcus (RO),Bathinda
	<b>Panelist</b>	Dr. Murtaza Bohra, Nagpur(MO)
01:56- 02:01 PM	<b>Take Home Message (5 mins)</b>	Dr Vineet Talwar,Delhi/ Dr Ram Alva, Bangalore (RO)
02:01-02:45 PM	<b>Lunch</b>	
02:45-03:00 PM	<b>Quiz for all</b>	
	<b>Chairperson</b>	Dr Vineet Talwar, Delhi
03:00-03:20 PM	<b>Importance of molecular testing in advanced prostate cancer</b>	Dr. Santosh Menon, Mumbai(MO)
03:20- 03:50 PM	<b>Pharma Sponsored Session-1</b>	Dr. Senthil Rajappa
	<b>Session Coordinator</b>	Dr. Anshuman Singh,Gurugram(UO)
	<b>SESSION 4- Renal Cell Carcinoma</b>	
	<b>Chairpersons</b>	Dr. Anant Kumar, Max saket, (UO) Dr. Rajesh Taneja, Apollo Delhi (UO) Dr. Subhash Gupta (RO, AIIMS Delhi) (RO)
03:50- 03:57 PM	Randomized Controlled Feasibility Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy: The ROBOCOP II Study	Dr. Himanshu Pandey, Varanasi (UO)
03:57- 04:04 PM	TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II	Dr. Mangesh Patil (RO), Nagpur

04:04- 04:11 PM	Cancer-specific Mortality in T1a Renal Cell Carcinoma Treated with Local Tumor Destruction Versus Partial Nephrectomy	Dr Vikas Agarwal, Akash Hospital, Delhi (UO)
04:11- 04:23 PM	Off-clamp versus on-clamp robot-assisted partial nephrectomy: A propensity-matched analysis Off-clamp Versus On-clamp Robot-assisted Partial Nephrectomy: A Systematic Review and Quantitative Synthesis by the European Association of Urology Young Academic Urologists Renal Cancer Study Group	Dr Mayank Aggarwal, Delhi(UO)
04:23- 04:30 PM	Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial [ASCO GU 2024]	Dr Suparna Rao, Mumbai (MO)
04:30- 04:35 PM	<b>Expert Comments</b>	By Chairperson
04:35- 05:05 PM	<b>Panel Discussion on above abstracts</b>	
	<b>Moderator</b>	Dr. Srivatsan Narsimhan, Bengaluru (UO)
	<b>Panelist</b>	Dr. Himesh Gandhi, Pune (UO)
	<b>Panelist</b>	Dr. Ginil Kumar, Kochi (UO)
	<b>Panelist</b>	Dr. B Kashyapi, Pune (UO)
	<b>Panelist</b>	Dr. Anup Kumar, Delhi (UO)
	<b>Panelist</b>	Dr. Renu Madan, Chandigarh (RO)
	<b>Panelist</b>	Dr. Aditi Aggarwal, Delhi(RO)
	<b>Panelist</b>	Dr. Kapil Raut, Nagpur (MO)
05:05- 05:15 PM	<b>Take Home message</b>	Dr. Rakesh Sharma, Hyderabad (UO)
	<b>Pharma Sponsored Session-2</b>	
05:15- 5:55 PM	<b>Panel Discussion-</b> Improving Survival and Quality of Life in frontline advanced RCC with CTLA-4 & PD-1 inhibition	
	<b>Moderator:</b>	Dr Nitesh Rohatgi, Delhi
	<b>Panelist:</b>	Dr Murtaza Bohra, Nagpur
		Dr Kapil Raut, Nagpur
		Dr Shantanu pendse, Nagpur
		Dr. Rushabh Kothari, Ahmedabad( MO)
05:55- 06:15 PM	<b>Tea Break</b>	
	<b>Session 5: Metastatic RCC</b>	
	<b>Session Coordinator</b>	Dr. Akhil Kapoor, Varanasi (MO)
	<b>Chairpersons:</b>	Dr. Amit Joshi, Mumbai (MO) Dr BK Mishra, Allahabad(MO) Dr. Sankalp Singh (RO, AHRR Delhi)
06:15- 06:22 PM	Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium	Dr. Amitabh Singh, Delhi (UO)
06:22- 06:34 PM	Subcutaneous nivolumab (NIVOSC) vs intravenous nivolumab (NIVOIV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC):Pharmacokinetics (PK),efficacy,and safety results from CheckMate67T [ASCO GU 2023 LBA 360] LITESPARK-005 Belzutifan Versus Everolimus in Participants with Previously Treated Advanced Clear Cell Renal Cell Carcinoma: Randomized Open-Label Phase 3	Dr. Sudeep Das, Kolkata(MO)
06:34- 06:46 PM	Nivolumab plus cabozantinib(N+C) vs sunitinib(S) forpreviously untreated advanced renal cell carcinoma (aRCC): Results from55-month follow-upof the CheckMate9ERtrial Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib( SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-update from the phase3 CheckMate214 trial	Dr Ram Abhinav (MO) , Coimbatore
06:46- 06:53 PM	Effect of CMB588 in combination with Cabozantinib plus Nivolumab for patients with mRCC: A randomised clinical trial (ASCO GU 2023)	Dr. Raajit Chanana, Delhi (MO)
06:53- 07:05 PM	CABOSUN II: Results from a Phase 2, Open-Label, Multi-Center Randomized Study of Cabozantinib vs. Sunitinib for Non-Clear Cell RCC First-Line Lenvatinib + Pembrolizumab Treatment Across Non-Clear Cell Renal Cell Carcinomas: Results of the Phase 2 KEYNOTE-B61 Study	Dr. Kunal Jonbanputra,(MO) Mumbai
07:05- 07:17 PM	Real-world practice patterns, treatment-related toxicity,and survival outcomes in older patients with metastatic renal cell carcinoma:Results from the Canadian Kidney Cancer information system (CKCis) Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients	Dr. Sandeep Batra, Gurugram (MO)
07:17- 07:22 PM	<b>Expert Comments</b>	By Chairperson
07:22- 07:52 PM	<b>Panel Discussion on above abstracts</b>	
	<b>Moderator</b>	Dr Atul Batra (MO), Delhi
	<b>Panelist</b>	Dr. Sajjan Rajpurohit, Delhi ( MO)
	<b>Panelist</b>	Dr Kaushal Kalra, Delhi( MO)
	<b>Panelist</b>	Dr. Rushabh Kothari, Ahmedabad( MO)
	<b>Panelist</b>	Dr. Vaibhav Amale, Kolhapur (MO)
	<b>Panelist</b>	Dr. Gunjesh Singh, Ranchi (MO)
	<b>Panelist</b>	Dr Anshul Agarwal, Surat(MO)
	<b>Panelist</b>	Dr. Himanshu Pandey, Varanasi (UO)
07:52- 08:02 PM	<b>Take Home message</b>	Dr. Randeep Singh, Gurugram(MO)
08:02- 08:12 PM	<b>Pharma Sponsored Session-3</b>	

08:12- 08:20 PM	<b>Closing Remarks Followed by Dinner</b>		
<b>05th Knowledge Series for Genitourinary Cancers - Best of 2023</b> Day 2   12th May ,2024 Venue- The Pride Aero City Delhi			
Time	Topic	Speaker	
	<b>Welcome and Introduction</b>		
	<b>SESSION 1</b>		
	<b>Session Coordinator</b>	<b>Dr Gagan Talwar,Delhi(UO)</b>	
	<b>Urothelial Cancer</b>		
	<b>Chairpersons</b>	<b>Dr. NP Gupta,Delhi(UO)</b> <b>Dr Samit Chaturvedi,Delhi (UO)</b> <b>Dr. Kishore Singh , Delhi(RO)</b>	
09:00-09:07 AM	En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial	<b>Dr Harkirat Talwar,Delhi(UO)</b>	
09:07-09:14 AM	Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer	<b>Dr Shrikanth Aturi, Mumbai(UO)</b>	
09:14-09:21 AM	DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial	<b>Dr Milap Shah,Ahemdabad(UO)</b>	
09:21-09:28 AM	Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis	<b>Dr Saurabh Patil,Mumbai(UO)</b>	
09:28-09:35 AM	SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.	<b>Dr Shanky Singh,Chandigarh(UO)</b>	
09:35- 09:45 AM	IROC Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-Year Outcomes from a Randomised Controlled Trial	<b>Dr. Vivek Venkatramani ,Mumbai(UO)</b>	
09:45- 09:55 AM	Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report	<b>Dr Ritesh Goyal,Faridabad(UO)</b>	
09:55-10:02 AM	Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer	<b>Dr. Irfan Bashir, Delhi(RO)</b>	
10:02-10:07 AM	<b>Expert Comments</b>	By Chairperson	
10:07 -10:37 AM	<b>Panel Discussion</b>		
	<b>Moderator</b>	<b>Dr Ganesh Bakshi,Mumbai(UO)</b>	
	<b>Panelist</b>	<b>Dr. Yuvraj TB,Mumbai(UO)</b>	
	<b>Panelist</b>	<b>Dr. Tarachand Gupta,Jaipur(MO)</b>	
	<b>Panelist</b>	TBC (RO)	
	<b>Panelist</b>	<b>Dr YPS Rana,Delhi(UO)</b>	
	<b>Panelist</b>	<b>Dr Aditya Pradhan,Delhi(UO)</b>	
	<b>Panelist</b>	<b>Dr. Umesh Sharma ,Delhi(UO)</b>	
	<b>Panelist</b>	<b>Dr. Hemant Goel,Delhi (UO)</b>	
10:37 -10:47 AM	<b>Take Home message</b>	<b>Dr. Sanket Kankaria,(UO)</b>	
	<b>SESSION 2</b>		
	<b>Urothelial Metastatic</b>		
	<b>Session Coordinator</b>	<b>Dr. HS Darling,Bangalore(MO)</b> <b>Dr Shyam Aggarwal, Delhi(MO)</b>	
	<b>Chairperson</b>		
10:47-10:54 AM	A Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study. (ASCO GU 2024 abst 537)	<b>Dr Rajat Bajaj,Delhi(Mo)</b>	
10:54-11:01 AM	HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer.(Abstract 538 ASCO GU24)	<b>Dr Annu Rajpurohit,Jaipur</b>	
11:01-11:08 AM	Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt). (ASCO 2023)	<b>Dr. Swaratika Majumdar,(MO) Bangalore</b>	
11:08-11:15 AM	EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). (ESMO 23 LBA6)	<b>Dr Sumant Gupta Delhi ( MO)</b>	
11:15-11:22 AM	Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial. NEJM Nov 23 (also ESMO 23 LBA-7)	<b>Dr. Somnath Roy, Kolkata( MO)</b>	
11:22-11:27 AM	<b>Expert Comments</b>	By Chairperson	
11:27-11:57 AM	<b>Panel Discussion</b>		
	<b>Moderator</b>	<b>Dr. Ranjit Sahoo Aiims Delhi(MO)</b>	
	<b>Panelist</b>	<b>Dr Mridul Malhotra,Gurgaon(MO)</b>	
	<b>Panelist</b>	<b>Dr. Abhishek Raj, Faridabad (MO)</b>	
	<b>Panelist</b>	<b>Dr Vikas Talreja (MO), Kanpur</b>	

	<b>Panelist</b>	<b>Dr Rohit Pai, Mumbai (MO)</b>	
	<b>Panelist</b>	<b>Dr. Shantanu Pendse, (MO)Nagpur</b>	
	<b>Panelist</b>	<b>Dr. Sunil Chopade,(MO)Mumbai</b>	
	<b>Panelist</b>	Dr Aseem samar Jaipur	
11:57 -12:07 PM	<b>Take Home Message</b>	<b>Dr Vijay Patil,Mumbai(MO)</b>	
12:07- 12:37 PM	<b>Pharma Sponsored Session-1</b>	Merck	
	<b>Pharma Sponsored Session-2</b>		
12:37- 12:57 PM	Role of Opdyta in Adjuvant treatment of adult patients with Urothelial Carcinoma (UC) who are at high risk of recurrence after undergoing radical resection.	Dr. MV Chandrakant,Mumbai	
	<b>Pharma Sponsored Session-3</b>	Bayer	
12:57- 01:17 PM	Recent Updates from ARASENS study presented at ASCO GU 2024	Dr. Akhil Kapoor	
01:17 - 01:37 PM	<b>QUIZ 2</b>		
	<b>Miscellaneous Abstract</b>		
	<b>Chairperson</b>	TBC(RO)	
01:37 - 01:44 PM	A Prospective Study of Chemoradiotherapy as Primary Treatment in Patients With Locoregionally Advanced Penile Carcinoma	<b>Dr. Prashant (RO- TMH Varanasi)</b>	
01:44 - 01:51 PM	Prognostic Factors for Relapse in Patients With Clinical Stage I Testicular Seminoma: A Nationwide, Population-Based Cohort Study	<b>Dr Priti Agarwal,Jaipur (MO)</b>	
01:51-02:00 PM	<b>Closing Remarks followed by lunch</b>	Dr. Kumar prabhash, Mumbai (MO)	